Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine

Inclusion Criteria

• •Patients with type 2diabetes inadequately controlled on a combination of OAD + NPH insulin for more than three months
• •Stable OAD therapy for at least three months, according to the following specified daily dose: glibenclamide\> 3, 5 mg, glipizid \>5 mg, glimeperid \>2mg, metformin\>1000 mg, acarbose \>150 mg
• •HbA1c \> 7,0%
• •Ability to perform QoL assessment
• •Body Mass Indes: women \<30 and men \<32
• •Exlusion criteria:
• •Autoimmune diabetes, as defined by WHO
• •Ongoing treatment with tiasolidindion drug
• •Retinopathy with surgical treatment during preceding three months of study entry or requiring treatment within three months after study entry
• •Drug abuse
• •Hypersensitivity to insulin glagine excipients
• •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.